170 related articles for article (PubMed ID: 34601813)
1. BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer.
Elazezy M; Prieske K; Kluwe L; Oliveira-Ferrer L; Peine S; Müller V; Woelber L; Schmalfeldt B; Pantel K; Joosse SA
Mol Oncol; 2021 Dec; 15(12):3615-3625. PubMed ID: 34601813
[TBL] [Abstract][Full Text] [Related]
2. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R
Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic inactivation of BRCA1 through promoter hypermethylation in ovarian cancer progression.
Wang YQ; Yan Q; Zhang JR; Li SD; Yang YX; Wan XP
J Obstet Gynaecol Res; 2013 Feb; 39(2):549-54. PubMed ID: 23006047
[TBL] [Abstract][Full Text] [Related]
4. Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients: A Study of the Tumor Bank Ovarian Cancer Consortium.
Sun T; Ruscito I; Dimitrova D; Chekerov R; Kulbe H; Baron U; Blanchard V; Panici PB; Darb-Esfahani S; Sehouli J; Olek S; Braicu EI
Int J Gynecol Cancer; 2017 Oct; 27(8):1658-1665. PubMed ID: 28691938
[TBL] [Abstract][Full Text] [Related]
5. BRCA1 promoter hypermethylation and protein expression in ovarian carcinoma--an Indian study.
Shilpa V; Bhagat R; Premalata CS; Pallavi VR; Ramesh G; Krishnamoorthy L
Tumour Biol; 2014 May; 35(5):4277-84. PubMed ID: 24385383
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of promoter hypermethylation of tumor suppressor gene BRCA1 in epithelial ovarian cancer.
Das J; Chandra L; Gandhi G; Amle DB; Patnayak RL; Khurana N; Saxena A
J Cancer Res Ther; 2022; 18(6):1578-1582. PubMed ID: 36412414
[TBL] [Abstract][Full Text] [Related]
7. BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).
Ruscito I; Dimitrova D; Vasconcelos I; Gellhaus K; Schwachula T; Bellati F; Zeillinger R; Benedetti-Panici P; Vergote I; Mahner S; Cacsire-Tong D; Concin N; Darb-Esfahani S; Lambrechts S; Sehouli J; Olek S; Braicu EI
Eur J Cancer; 2014 Aug; 50(12):2090-8. PubMed ID: 24889916
[TBL] [Abstract][Full Text] [Related]
8. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.
Baldwin RL; Nemeth E; Tran H; Shvartsman H; Cass I; Narod S; Karlan BY
Cancer Res; 2000 Oct; 60(19):5329-33. PubMed ID: 11034065
[TBL] [Abstract][Full Text] [Related]
9. Identifying the BRCA1 c.-107A > T variant in Dutch patients with a tumor BRCA1 promoter hypermethylation.
de Jong VMT; Pruntel R; Steenbruggen TG; Bleeker FE; Nederlof P; Hogervorst FBL; Linn SC
Fam Cancer; 2023 Apr; 22(2):151-154. PubMed ID: 36112334
[TBL] [Abstract][Full Text] [Related]
10. Genetic and epigenetic profiling of BRCA1/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1/2 DNA methylation signature.
Aref-Eshghi E; McGee JD; Pedro VP; Kerkhof J; Stuart A; Ainsworth PJ; Lin H; Volodarsky M; McLachlin CM; Sadikovic B
J Hum Genet; 2020 Oct; 65(10):865-873. PubMed ID: 32483276
[TBL] [Abstract][Full Text] [Related]
11. Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer.
Rusan M; Andersen RF; Jakobsen A; Steffensen KD
Eur J Cancer; 2020 Jan; 125():121-129. PubMed ID: 31865042
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients.
Sharma G; Mirza S; Parshad R; Srivastava A; Gupta SD; Pandya P; Ralhan R
Life Sci; 2010 Jul; 87(3-4):83-91. PubMed ID: 20470789
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.
Bernards SS; Pennington KP; Harrell MI; Agnew KJ; Garcia RL; Norquist BM; Swisher EM
Gynecol Oncol; 2018 Feb; 148(2):281-285. PubMed ID: 29233532
[TBL] [Abstract][Full Text] [Related]
14. High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors.
Wilcox CB; Baysal BE; Gallion HH; Strange MA; DeLoia JA
Cancer Genet Cytogenet; 2005 Jun; 159(2):114-22. PubMed ID: 15899382
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 promoter methylation is a marker of better response to platinum-taxane-based therapy in sporadic epithelial ovarian cancer.
Ignatov T; Eggemann H; Costa SD; Roessner A; Kalinski T; Ignatov A
J Cancer Res Clin Oncol; 2014 Sep; 140(9):1457-63. PubMed ID: 24825122
[TBL] [Abstract][Full Text] [Related]
16. Association of folate and other one-carbon related nutrients with hypermethylation status and expression of RARB, BRCA1, and RASSF1A genes in breast cancer patients.
Pirouzpanah S; Taleban FA; Mehdipour P; Atri M
J Mol Med (Berl); 2015 Aug; 93(8):917-34. PubMed ID: 25805039
[TBL] [Abstract][Full Text] [Related]
17. Promoter Hypermethylation and Expression Changes of BRCA1 Gene in a Cohort of Sporadic Breast Cancer Cases among Pakistani Population.
Arif T; Anwar N
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2395-2401. PubMed ID: 32856871
[TBL] [Abstract][Full Text] [Related]
18. Methylation status and immunohistochemistry of BRCA1 in epithelial ovarian cancer.
Pradjatmo H; Dasuki D; Anwar M; Mubarika S; Harijadi
Asian Pac J Cancer Prev; 2014; 15(21):9479-85. PubMed ID: 25422243
[TBL] [Abstract][Full Text] [Related]
19. Curcumin induces re‑expression of BRCA1 and suppression of γ synuclein by modulating DNA promoter methylation in breast cancer cell lines.
Al-Yousef N; Shinwari Z; Al-Shahrani B; Al-Showimi M; Al-Moghrabi N
Oncol Rep; 2020 Mar; 43(3):827-838. PubMed ID: 32020216
[TBL] [Abstract][Full Text] [Related]
20. BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis.
Kalachand RD; Stordal B; Madden S; Chandler B; Cunningham J; Goode EL; Ruscito I; Braicu EI; Sehouli J; Ignatov A; Yu H; Katsaros D; Mills GB; Lu KH; Carey MS; Timms KM; Kupryjanczyk J; Rzepecka IK; Podgorska A; McAlpine JN; Swisher EM; Bernards SS; O'Riain C; O'Toole S; O'Leary JJ; Bowtell DD; Thomas DM; Prieske K; Joosse SA; Woelber L; Chaudhry P; Häfner N; Runnebaum IB; Hennessy BT
J Natl Cancer Inst; 2020 Dec; 112(12):1190-1203. PubMed ID: 32413141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]